

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Shalaby Shalaby, Anderson, :
SC (US)

APPLICATION NO.: 10/693,383 : Examiner: SILVERMAN, ERIC
E.

FILING DATE: 10-24-2003 : Group Art Unit: 1615

TITLE: SOLID AND SEMI-SOLID POLYMERIC :
IONIC CONJUGATES

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references:

- 1) International Search Report for PCT/IB03/04699
- 2) U.S. 10/693,307 filed October 24, 2003 and currently pending
- 3) US 6,232,304
- 4) WO 99/12549
- 5) US 2002/076441 A1
- 6) WO 01/82970 A
- 7) EP 1269994
- 8) Kibbe, Handbook of Pharmaceutical Excipients Third Edition, pages 165 through 168, January 15, 2000

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

Patent Application
Attorney Docket No. PC25203A

Applicants have not supplied copies of items number 2, 3 and 5 indicated above as these are all documents available to the U.S. Patent Office. However, if the Examiner would like for applicants to submit copies of any of these references, applicants will gladly do so upon request.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge the fee under 37 CFR 1.17(p) to cover this submission to Pfizer Deposit Account No. 16-1445. No other fee is believed necessary for this Information Disclosure Statement. However, should any other fee for filing this Information Disclosure Statement be determined necessary, please charge such fee to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: May 25, 2007

/Kristina L. Konstas/
Kristina L. Konstas
Attorney for Applicants
Reg. No. 37,864

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733-6380